InvestSMART

Neurotech International Limited (ASX:NTI)

ALERT: Price-sensitive ASX Announcement for NTI
Current share price for NTI : $0.016 0.005 (45.45%)+
Announcement
Release
17 Mar 2026 9:32AM
Price at Release
$0.011
Full Release
download
Summary
Neurotech International Limited has announced the initiation of the first clinical site for the Phase 3 'Beyond Harmony' trial, which evaluates NTI164 in paediatric patients with Autism Spectrum Disorder (ASD). The trial, conducted at Monash Children's Hospital, is a multi-centre, randomised, double-blind, placebo-controlled study designed to assess the efficacy, safety, and tolerability of NTI164. The trial aims to enrol 150 patients using an adaptive trial design and focuses on addressing core symptoms of ASD and neuroinflammatory pathways. This marks a significant milestone for Neurotech, supporting its clinical development program and potential NTI164 commercialisation.
Key Points
  • First clinical site initiated for Phase 3 'Beyond Harmony' trial
  • Study evaluating NTI164 in paediatric patients with ASD
  • Multi-centre, randomised, double-blind, placebo-controlled design
  • Focus on core symptoms and neuroinflammatory mechanisms
  • 150 patients planned for enrolment under adaptive trial design
  • Monash Children's Hospital as first site activated
  • Significant milestone in Neurotech's clinical program
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.